Tej Kohli Foundation Seeks to Incubate New Projects That Can Eliminate Corneal Blindness By 2035
The Tej Kohli Foundation is to establish a new incubator to provide seed and acceleration funding to projects with the potential to help eliminate corneal blindness worldwide. Funding, practical resources and intellectual capital will be available to both commercial and non-commercial projects that have a clear path to the prevention, treatment and cure of corneal blindness; with funding decisions based on the magnitude of the total impact that a project will likely have in poor and underserved communities worldwide by 2035, as well as the likelihood that a project will succeed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200221005010/en/
Mrs. Gurujalli Tejavathi outside her home in the Bhadradri District in India. Mrs. Tejavathi receives free eye care for a previously transplanted cornea from the Tej Kohli Foundation. (Photo: Business Wire)
The Tej Kohli Foundation continues to build its position as a multi-disciplinary global centre of focus for the development and advancement of an affordable, scalable and accessible ‘universal solution’ for preventing and eliminating corneal blindness. The World Health Organisation says that 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. Whilst approximately 75% of corneal disease is curable by corneal transplant, the costs of invasive surgery, and the many years of medicine needed to prevent rejection after surgery, makes this form of treatment entirely inaccessible to the majority of the people in the world who suffer from severe visual impairment or corneal blindness.
Tej Kohli co-founded the eponymous Foundation in 2005 alongside wife Wendy Kohli. He has previously spoken about funding life-changing corneal transplants in poor and underserved communities as being “like Schindler’s List, you do a few, then you just have to do more” (https://www.telegraph.co.uk/technology/2019/10/04/tej-kohli-indian-tech-billionaire-plans-turbocharge-britains/). In December 2019 the Tej Kohli Foundation announced that it had restored the sight of 5,736 blind people during the year (https://www.businesswire.com/news/home/20191219005417/en/5736-World%E2%80%99s-Poorest-People-Received-Gift-Sight) and committed $14m of further funding to its Cornea Institute.
Tej Kohli is also an evangelist of the opportunities that can be derived from the chain reaction of technological progression and the impact that they can have on human life: https://www.spearswms.com/billionaire-philanthropist-tej-kohli-ai/. The new Tej Kohli Foundation incubator hopes to back projects that can leverage this chain reaction of technological progression to develop and deliver new techniques and applications and game-changing innovations for improving access. The Foundation is seeking to incubate between one and three new projects initially, and welcomes funding applications from all fields of expertise. Projects must show that they can make a significant impact by 2035.
The Tej Kohli Foundation funded its first donor cornea implants at Niramaya Hospital in India in 2010. After funding thousands of corneal transplants, in 2015 the Tej Kohli Foundation substantially expanded its efforts to tackle corneal blindness in poor and underserved communities with the ambitious launch the Tej Kohli Cornea Institute in Hyderabad. Between January 2016 and November 2019 the Tej Kohli Cornea Institute welcomed more than 223,404 outpatients and completed more than 43,255 surgical procedures. The Tej Kohli Foundation has also pursued a ‘universal treatment’ for corneal blindness through its ‘Applied Research’ program, which is a longstanding scientific collaboration between researchers in Montreal Canada, and Moorfields Eye Hospital in the UK.
In January 2020 seed funding from the Tej Kohli Foundation was granted to two new research projects. The first project will focus on preventing corneal endothelial cell loss, which is usually permanent and is the leading reason for corneal transplantation worldwide. The second project will use novel drugs released by contact lenses to treat ocular surface pain and overcome the need for opioids when treating severe eye pain, which remains one of the unmet needs in Ophthalmology.
Eligible projects are invited to submit a 2-page project abstract as a PDF to: project2035@tejkohlifoundation.com. Submissions will be considered by the Tej Kohli Foundation on a case-by-case basis in direct collaboration with its global network of specialists.
Wendy Kohli, co-Founder of the Tej Kohli Foundation said:
“The YouTube channel of the Tej Kohli Foundation has many stories of individuals who have been cured of severe visual impairment or corneal blindness. But the overwhelming majority of those living needlessly with blindness still cannot afford or access treatment. It is only through major innovations borne from research, science, technology and enterprise that we can move toward a world where nobody is needlessly blind because of poverty.”
Tej Kohli, co-Founder of the Tej Kohli Foundation said:
“There are many innovations already in the pipeline that could one day offer affordable, scalable and accessible solutions for prevention and cure in the poor and underserved communities where corneal blindness is most pervasive. At the Tej Kohli Foundation we are interested in backing and funding new innovations and projects that will accelerate progress toward the goal of eliminating poverty-driven corneal blindness worldwide by 2035.”
About the Tej Kohli Foundation:
Website: http://www.tejkohlifoundation.com
YouTube: https://www.youtube.com/c/tejkohlifoundation
About Tej Kohli:
Profile: https://www.tejkohlifoundation.com/tej-kohli
Twitter: https://twitter.com/mrtejkohli
About Wendy Kohli:
Profile: https://www.tejkohlifoundation.com/wendy-kohli
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200221005010/en/
Contact information
To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff
(Buchanan Communications)
tejkohlifoundation@buchanan.uk.com
+44 207 466 5000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Transition Industries Signs Strategic Agreements for the Pacifico Mexinol Project, the Largest Standalone Ultra-Low Carbon Chemical Production Facility in the World30.6.2025 21:30:00 EEST | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects in North America, held a signing event for an Engineering, Procurement, and Construction (EPC) contract with the consortium of Samsung E&A Co., Ltd. (Samsung E&A), Grupo Samsung E&A Mexico, S.A. de C.V., and Techint Engineering and Construction for the Pacifico Mexinol project located in Ahome, Sinaloa, Mexico, which is contingent upon the fulfillment of customary conditions precedent and obtainment of all required approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630940954/en/ MAIRE group’s technology division NextChem, through its subsidiary KT TECH SpA, also signed a Basic Engineering, Critical and Proprietary Equipment Supply Agreement with Samsung E&A in connection with its proprietary NX AdWinMethanol®Zero technology supply to the project. Transition Industries is jointly developing the Pacif
Westinghouse and ITER Sign a $180M Contract to Advance Nuclear Fusion30.6.2025 16:45:00 EEST | Press release
Westinghouse Electric Company and ITER signed a contract for $180 million for the assembly of the vacuum vessel for the fusion reactor. This is a key milestone in the construction of the ITER reactor, leading the way toward the use of fusion as a practical future source of reliable carbon-free energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630497810/en/ The ITER Tokamak pit with the two vacuum vessel sector modules installed. Westinghouse has participated in the fabrication of the sectors of the vacuum vessel, as part of the Fusion for Energy (F4E) Consortium with its partners Ansaldo Nucleare and Walter Tosto. Westinghouse will be responsible for completing the vacuum vessel which is ITER’s most critical component: a hermetically sealed, double-walled steel container that will house the fusion plasma. When all the vacuum vessel sectors are in place, Westinghouse will start the most intensive stage of ITER assembl
Monetate Acquires SiteSpect to Deliver AI-Native Personalization and Testing at Enterprise Scale30.6.2025 16:00:00 EEST | Press release
Monetate, the leading AI-driven personalization platform, today announced it has acquired SiteSpect, a leader in A/B testing, to drive next-generation digital experience optimization. This acquisition accelerates Monetate’s vision to deliver intelligent, intentional, and individualized experiences at scale, powered by agentic AI and backed by the industry’s most advanced, enterprise-grade infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630514541/en/ The combination of Monetate’s real-time personalization and SiteSpect’s zero-flicker testing will yield an industry-first solution for enterprise-grade personalization, testing, and optimization. For the first time, global ecommerce and digital experience leaders can access unified client-side and server-side experimentation with full personalization capabilities in a single solution, designed for scalability and regulatory compliance. Monetate is now the only e
SS&C Blue Prism Recognized as a Gartner® Magic Quadrant™ RPA Leader for the Seventh Consecutive Year30.6.2025 16:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that SS&C Blue Prism has been recognized as a Leader in the 2025 Gartner Magic Quadrant for Robotic Process Automation (RPA). “We’re delighted SS&C Blue Prism has been named a Leader in the Gartner Magic Quadrant for Robotic Process Automation for the seventh year running,” said Bill Stone, CEO and Chairman of SS&C Technologies. “SS&C Blue Prism combines market-leading RPA and orchestration technologies with the latest artificial intelligence so organizations can tackle more complex tasks and dynamic business processes. We’ve scaled to more than 2,700 digital workers and AI agents across our own operations, resulting in over $200 million in annual savings. With SS&C leading the charge on deployment, customers can be confident in rolling out SS&C’s automation solutions securely, effectively, and responsibly.” More than 2,800 companies worldwide leverage SS&C Blue Prism for AI-powered automation, helping organizations delive
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content 130.6.2025 15:00:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administration burden for patients and their health care providers by eliminating the need for reconstitution and can be administered intravenously or subcutaneously.1 “The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the lowest IgA content of any ready-to-use liquid immunoglobulin therapy, and can be administered intravenously or subcutaneously,” said Kristina Allikmets, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom